Mozart Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapies that effectively treat and potentially cure autoimmune disease.
Our first-in-class CD8 Treg modulators target a fundamental cause of immune dysregulation to restore durable immune homeostasis. For our patients suffering with autoimmune disease, this means re-establishing healthy immune system function and unburdening them from the harmful impacts of immune system disorders.
Our Science
We are advancing and expanding on Nobel award-winning science and the pioneering work of Professor Mark Davis ([1][2][3]), and progressing these scientific discoveries into the clinic.
Professor Davis was first to describe a network of immune cells responsible for regulating and maintaining immune tolerance—the mechanisms by which the immune system distinguishes “self” from “non-self” and protects against damage to healthy “self” tissue. Dr. Davis identified and characterized the breadth and functions of specialized immune cells called regulatory CD8 T cells (“CD8 Treg”). CD8 Treg are critical mediators of immune tolerance and responsible for maintaining a healthy immune system, sometimes called “immune homeostasis”.
In autoimmune disease, CD8 Treg have become dysfunctional, allowing the immune system to mistakenly attack “self” (healthy) tissue. Our first-in-class biologics are designed to restore healthy CD8 Treg function.
Pipeline
Mozart is advancing a pipeline of therapies that restore innate CD8 Treg functions. This innovative approach is designed to re-establish healthy immune system function and avert the chronic inflammation and progressive tissue damage caused by harmful autoimmune responses (i.e., immune responses directed at “self”).